2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignancies
Summary: Febrile Neutropenia is an emergency in the treatment of cancer patients. It requires prompt and evidence-based clinical and antimicrobial management. The implementation of standard operating procedures (SOP) across hospitals and outpatient cancer departments can improve the outcome of FN pa...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-04-01
|
| Series: | The Lancet Regional Health. Europe |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666776225000067 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832573030442729472 |
|---|---|
| author | Michael Sandherr Jannik Stemler Enrico Schalk Tessa Hattenhauer Marcus Hentrich Bernd Hertenstein Christian Hohmann Sibylle C. Mellinghoff Rebekka Mispelbaum Christina Rieger Martin Schmidt-Hieber Rosanne Sprute Guenter Weiss Oliver A. Cornely Larissa Henze Cornelia Lass-Floerl Gernot Beutel Annika Y. Classen Noemi F. Freise Meinolf Karthaus Philipp Koehler Robert Krause Julia Neuhann Hans Martin Orth Olaf Penack Markus Schaich Karsten Spiekermann Sebastian Voigt Florian Weissinger Elena Busch |
| author_facet | Michael Sandherr Jannik Stemler Enrico Schalk Tessa Hattenhauer Marcus Hentrich Bernd Hertenstein Christian Hohmann Sibylle C. Mellinghoff Rebekka Mispelbaum Christina Rieger Martin Schmidt-Hieber Rosanne Sprute Guenter Weiss Oliver A. Cornely Larissa Henze Cornelia Lass-Floerl Gernot Beutel Annika Y. Classen Noemi F. Freise Meinolf Karthaus Philipp Koehler Robert Krause Julia Neuhann Hans Martin Orth Olaf Penack Markus Schaich Karsten Spiekermann Sebastian Voigt Florian Weissinger Elena Busch |
| author_sort | Michael Sandherr |
| collection | DOAJ |
| description | Summary: Febrile Neutropenia is an emergency in the treatment of cancer patients. It requires prompt and evidence-based clinical and antimicrobial management. The implementation of standard operating procedures (SOP) across hospitals and outpatient cancer departments can improve the outcome of FN patients by reducing FN-related morbidity and mortality and by the continuation of cancer treatment. This guideline describes an evidence-based approach to risk stratification, epidemiology, diagnosis, and treatment. It is provided by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) and is an update of the 2017 version. Emerging aspects in epidemiology, diagnostic procedures, risk stratification, first-line antimicrobial treatment, empiric antifungal treatment and the duration of antimicrobial treatment are discussed and rated on evidence-based strength of recommendation and quality of evidence as described by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). By this, the aim of this guideline is to provide evidence-based recommendations on the management of febrile neutropenia in cancer patients for the practicing clinician. |
| format | Article |
| id | doaj-art-b1cf7e0290d94e3ea41775f1d23f4c49 |
| institution | Kabale University |
| issn | 2666-7762 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | The Lancet Regional Health. Europe |
| spelling | doaj-art-b1cf7e0290d94e3ea41775f1d23f4c492025-02-02T05:29:24ZengElsevierThe Lancet Regional Health. Europe2666-77622025-04-01511012142024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignanciesMichael Sandherr0Jannik Stemler1Enrico Schalk2Tessa Hattenhauer3Marcus Hentrich4Bernd Hertenstein5Christian Hohmann6Sibylle C. Mellinghoff7Rebekka Mispelbaum8Christina Rieger9Martin Schmidt-Hieber10Rosanne Sprute11Guenter Weiss12Oliver A. Cornely13Larissa Henze14Cornelia Lass-Floerl15Gernot Beutel16Annika Y. Classen17Noemi F. Freise18Meinolf Karthaus19Philipp Koehler20Robert Krause21Julia Neuhann22Hans Martin Orth23Olaf Penack24Markus Schaich25Karsten Spiekermann26Sebastian Voigt27Florian Weissinger28Elena Busch29Specialist Clinic for Hematology and Oncology, Medical Care Center Penzberg, Germany; Corresponding author.University of Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany; University of Cologne, Faculty of Medicine, and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Cologne, Germany; German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne Department, Cologne, GermanyDepartment of Hematology, Oncology and Cell Therapy, Medical Faculty, Otto von Guericke University Magdeburg, Magdeburg, GermanyDepartment of Oncology, Hematology, Rheumatology and Immune-Oncology, University Hospital Bonn, Bonn, GermanyDepartment of Hematology and Oncology, Red Cross Hospital Munich, Ludwig Maximilian University Munich, Munich, GermanyDepartment of Medicine, Clinic I - Hematology, Oncology, Infectiology, Department of Intensive Care and Emergency Medicine, Klinikum Bremen-Mitte, Bremen, GermanyDepartment of Medicine, Clinic I - Hematology, Oncology, Infectiology, Department of Intensive Care and Emergency Medicine, Klinikum Bremen-Mitte, Bremen, GermanyUniversity of Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany; University of Cologne, Faculty of Medicine, and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Cologne, Germany; German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne Department, Cologne, GermanyDepartment of Oncology, Hematology, Rheumatology and Immune-Oncology, University Hospital Bonn, Bonn, GermanyDepartment of Hematology and Oncology Germering, Germering, GermanyClinic for Oncology, Hematology, Pneumology, Nephrology and Diabetology, Carl-Thiem Clinic, Cottbus, GermanyUniversity of Cologne, Faculty of Medicine, and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Cologne, GermanyDepartment of Internal Medicine II, Infectious Diseases, Immunology, Rheumatology, Pneumology, Medical University of Innsbruck, Innsbruck, AustriaUniversity of Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany; University of Cologne, Faculty of Medicine, and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Cologne, Germany; German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne Department, Cologne, GermanyDepartment of Medicine, Clinic III - Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, Rostock, Germany; Department of Internal Medicine II, Hematology, Oncology and Palliative Medicine, Asklepios Hospital Harz, Goslar, GermanyInstitut of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, AustriaDepartment of Internal Medicine, Hematology, Oncology and Stem Cell Transplantation, Medical University of Hannover, Hannover, GermanyUniversity of Cologne, Faculty of Medicine, and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Cologne, Germany; German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, GermanyDepartment of Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), GermanyDepartment Hematology, Oncology and Palliative Care, Klinikum Neuperlach and Harlaching, Munich, GermanyUniversity of Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, GermanyDivision of Infectious Diseases, Department of Internal Medicine, Medical University of Graz, Austria; BioTechMed, Graz, AustriaUniversity of Cologne, Faculty of Medicine, and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Cologne, GermanyDepartment of Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), GermanyCharité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Tumorimmunology, Berlin, GermanyDepartment of Hematology, Oncology and Palliative Care, Rems-Murr-Klinikum Winnenden, GermanyDepartment of Medicine III, LMU University Hospital, LMU Munich, GermanyInstitute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, GermanyEvangelic Hospital Bethel, Bielefeld, GermanyInternal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, GermanySummary: Febrile Neutropenia is an emergency in the treatment of cancer patients. It requires prompt and evidence-based clinical and antimicrobial management. The implementation of standard operating procedures (SOP) across hospitals and outpatient cancer departments can improve the outcome of FN patients by reducing FN-related morbidity and mortality and by the continuation of cancer treatment. This guideline describes an evidence-based approach to risk stratification, epidemiology, diagnosis, and treatment. It is provided by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) and is an update of the 2017 version. Emerging aspects in epidemiology, diagnostic procedures, risk stratification, first-line antimicrobial treatment, empiric antifungal treatment and the duration of antimicrobial treatment are discussed and rated on evidence-based strength of recommendation and quality of evidence as described by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). By this, the aim of this guideline is to provide evidence-based recommendations on the management of febrile neutropenia in cancer patients for the practicing clinician.http://www.sciencedirect.com/science/article/pii/S2666776225000067Febrile NeutropeniaCancerLeukemiaAntimicrobial treatmentAlgorithmEvidence-based guideline |
| spellingShingle | Michael Sandherr Jannik Stemler Enrico Schalk Tessa Hattenhauer Marcus Hentrich Bernd Hertenstein Christian Hohmann Sibylle C. Mellinghoff Rebekka Mispelbaum Christina Rieger Martin Schmidt-Hieber Rosanne Sprute Guenter Weiss Oliver A. Cornely Larissa Henze Cornelia Lass-Floerl Gernot Beutel Annika Y. Classen Noemi F. Freise Meinolf Karthaus Philipp Koehler Robert Krause Julia Neuhann Hans Martin Orth Olaf Penack Markus Schaich Karsten Spiekermann Sebastian Voigt Florian Weissinger Elena Busch 2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignancies The Lancet Regional Health. Europe Febrile Neutropenia Cancer Leukemia Antimicrobial treatment Algorithm Evidence-based guideline |
| title | 2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignancies |
| title_full | 2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignancies |
| title_fullStr | 2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignancies |
| title_full_unstemmed | 2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignancies |
| title_short | 2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignancies |
| title_sort | 2024 update of the agiho guideline on diagnosis and empirical treatment of fever of unknown origin fuo in adult neutropenic patients with solid tumours and hematological malignancies |
| topic | Febrile Neutropenia Cancer Leukemia Antimicrobial treatment Algorithm Evidence-based guideline |
| url | http://www.sciencedirect.com/science/article/pii/S2666776225000067 |
| work_keys_str_mv | AT michaelsandherr 2024updateoftheagihoguidelineondiagnosisandempiricaltreatmentoffeverofunknownoriginfuoinadultneutropenicpatientswithsolidtumoursandhematologicalmalignancies AT jannikstemler 2024updateoftheagihoguidelineondiagnosisandempiricaltreatmentoffeverofunknownoriginfuoinadultneutropenicpatientswithsolidtumoursandhematologicalmalignancies AT enricoschalk 2024updateoftheagihoguidelineondiagnosisandempiricaltreatmentoffeverofunknownoriginfuoinadultneutropenicpatientswithsolidtumoursandhematologicalmalignancies AT tessahattenhauer 2024updateoftheagihoguidelineondiagnosisandempiricaltreatmentoffeverofunknownoriginfuoinadultneutropenicpatientswithsolidtumoursandhematologicalmalignancies AT marcushentrich 2024updateoftheagihoguidelineondiagnosisandempiricaltreatmentoffeverofunknownoriginfuoinadultneutropenicpatientswithsolidtumoursandhematologicalmalignancies AT berndhertenstein 2024updateoftheagihoguidelineondiagnosisandempiricaltreatmentoffeverofunknownoriginfuoinadultneutropenicpatientswithsolidtumoursandhematologicalmalignancies AT christianhohmann 2024updateoftheagihoguidelineondiagnosisandempiricaltreatmentoffeverofunknownoriginfuoinadultneutropenicpatientswithsolidtumoursandhematologicalmalignancies AT sibyllecmellinghoff 2024updateoftheagihoguidelineondiagnosisandempiricaltreatmentoffeverofunknownoriginfuoinadultneutropenicpatientswithsolidtumoursandhematologicalmalignancies AT rebekkamispelbaum 2024updateoftheagihoguidelineondiagnosisandempiricaltreatmentoffeverofunknownoriginfuoinadultneutropenicpatientswithsolidtumoursandhematologicalmalignancies AT christinarieger 2024updateoftheagihoguidelineondiagnosisandempiricaltreatmentoffeverofunknownoriginfuoinadultneutropenicpatientswithsolidtumoursandhematologicalmalignancies AT martinschmidthieber 2024updateoftheagihoguidelineondiagnosisandempiricaltreatmentoffeverofunknownoriginfuoinadultneutropenicpatientswithsolidtumoursandhematologicalmalignancies AT rosannesprute 2024updateoftheagihoguidelineondiagnosisandempiricaltreatmentoffeverofunknownoriginfuoinadultneutropenicpatientswithsolidtumoursandhematologicalmalignancies AT guenterweiss 2024updateoftheagihoguidelineondiagnosisandempiricaltreatmentoffeverofunknownoriginfuoinadultneutropenicpatientswithsolidtumoursandhematologicalmalignancies AT oliveracornely 2024updateoftheagihoguidelineondiagnosisandempiricaltreatmentoffeverofunknownoriginfuoinadultneutropenicpatientswithsolidtumoursandhematologicalmalignancies AT larissahenze 2024updateoftheagihoguidelineondiagnosisandempiricaltreatmentoffeverofunknownoriginfuoinadultneutropenicpatientswithsolidtumoursandhematologicalmalignancies AT cornelialassfloerl 2024updateoftheagihoguidelineondiagnosisandempiricaltreatmentoffeverofunknownoriginfuoinadultneutropenicpatientswithsolidtumoursandhematologicalmalignancies AT gernotbeutel 2024updateoftheagihoguidelineondiagnosisandempiricaltreatmentoffeverofunknownoriginfuoinadultneutropenicpatientswithsolidtumoursandhematologicalmalignancies AT annikayclassen 2024updateoftheagihoguidelineondiagnosisandempiricaltreatmentoffeverofunknownoriginfuoinadultneutropenicpatientswithsolidtumoursandhematologicalmalignancies AT noemiffreise 2024updateoftheagihoguidelineondiagnosisandempiricaltreatmentoffeverofunknownoriginfuoinadultneutropenicpatientswithsolidtumoursandhematologicalmalignancies AT meinolfkarthaus 2024updateoftheagihoguidelineondiagnosisandempiricaltreatmentoffeverofunknownoriginfuoinadultneutropenicpatientswithsolidtumoursandhematologicalmalignancies AT philippkoehler 2024updateoftheagihoguidelineondiagnosisandempiricaltreatmentoffeverofunknownoriginfuoinadultneutropenicpatientswithsolidtumoursandhematologicalmalignancies AT robertkrause 2024updateoftheagihoguidelineondiagnosisandempiricaltreatmentoffeverofunknownoriginfuoinadultneutropenicpatientswithsolidtumoursandhematologicalmalignancies AT julianeuhann 2024updateoftheagihoguidelineondiagnosisandempiricaltreatmentoffeverofunknownoriginfuoinadultneutropenicpatientswithsolidtumoursandhematologicalmalignancies AT hansmartinorth 2024updateoftheagihoguidelineondiagnosisandempiricaltreatmentoffeverofunknownoriginfuoinadultneutropenicpatientswithsolidtumoursandhematologicalmalignancies AT olafpenack 2024updateoftheagihoguidelineondiagnosisandempiricaltreatmentoffeverofunknownoriginfuoinadultneutropenicpatientswithsolidtumoursandhematologicalmalignancies AT markusschaich 2024updateoftheagihoguidelineondiagnosisandempiricaltreatmentoffeverofunknownoriginfuoinadultneutropenicpatientswithsolidtumoursandhematologicalmalignancies AT karstenspiekermann 2024updateoftheagihoguidelineondiagnosisandempiricaltreatmentoffeverofunknownoriginfuoinadultneutropenicpatientswithsolidtumoursandhematologicalmalignancies AT sebastianvoigt 2024updateoftheagihoguidelineondiagnosisandempiricaltreatmentoffeverofunknownoriginfuoinadultneutropenicpatientswithsolidtumoursandhematologicalmalignancies AT florianweissinger 2024updateoftheagihoguidelineondiagnosisandempiricaltreatmentoffeverofunknownoriginfuoinadultneutropenicpatientswithsolidtumoursandhematologicalmalignancies AT elenabusch 2024updateoftheagihoguidelineondiagnosisandempiricaltreatmentoffeverofunknownoriginfuoinadultneutropenicpatientswithsolidtumoursandhematologicalmalignancies |